Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/18/2010CA2761946A1 Carcinoma diagnosis and treatment, based on odc1 genotype
11/18/2010CA2761940A1 Methods of treating proliferative diseases
11/18/2010CA2761932A1 L-arabinose plus chromium for controlling the metabolization of sucrose
11/18/2010CA2761901A1 Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
11/18/2010CA2761881A1 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
11/18/2010CA2761880A1 2'-fluoro arabino nucleosides and use thereof
11/18/2010CA2761876A1 Haloalkyl heteroaryl benzamide compounds
11/18/2010CA2761859A1 Aryl pyridine as aldosterone synthase inhibitors
11/18/2010CA2761858A1 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
11/18/2010CA2761853A1 Benzoxazolone derivatives as aldosterone synthase inhibitors
11/18/2010CA2761845A1 Thiophene[3,4-c]pyrrole pde4 mediators
11/18/2010CA2761801A1 Compositions and methods for drug delivery
11/18/2010CA2761798A1 Compositions and methods for treating ischemia and ischemia-reperfusion injury
11/18/2010CA2761795A1 Burst drug release compositions
11/18/2010CA2761771A1 Ranolazine for the treatment of cns disorders
11/18/2010CA2761756A1 Treatment of urinary tract infections with antibacterial aminoglycoside compounds
11/18/2010CA2761740A1 Phosphate-free pharmaceutical composition for the treatment of glaucoma
11/18/2010CA2761739A1 Oil-in-water emulsion of mometasone and propylene glycol
11/18/2010CA2761732A1 Composition for preventing hair loss or for stimulating hair growth
11/18/2010CA2761717A1 Methods for treatment of oncological disorders using epimetabolic shifters, multdimensional intracellular molecules, or environmental influencers
11/18/2010CA2761716A1 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
11/18/2010CA2761674A1 Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds
11/18/2010CA2761663A1 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
11/18/2010CA2761660A1 Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation thereof, and therapeutic use thereof
11/18/2010CA2761658A1 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
11/18/2010CA2761656A1 Amorphous silibinin for the treatment of viral hepatitis
11/18/2010CA2761650A1 Macrocyclic compounds as hepatitis c virus inhibitors
11/18/2010CA2761628A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
11/18/2010CA2761627A1 Sulphated hyaluronic acids as regulator agents of the cytokine activity
11/18/2010CA2761602A1 Desfesoterodine in the form of a tartaric acid salt
11/18/2010CA2761595A1 Polyketide compound
11/18/2010CA2761469A1 Lysine compounds and their use in site- and chemoselective modification of peptides and proteins
11/18/2010CA2761455A1 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
11/18/2010CA2761446A1 Infant and young children feeding formula comprising probiotics for infants and young children
11/18/2010CA2761258A1 Antiviral compounds
11/18/2010CA2761256A1 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
11/18/2010CA2761255A1 Solid forms and process for preparing
11/18/2010CA2761243A1 Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
11/18/2010CA2761049A1 Method of decreasing ubiquitylated protein levels
11/18/2010CA2760981A1 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
11/18/2010CA2760837A1 7-([1,2,4]triazolo[1,5,-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
11/18/2010CA2760778A1 Heteroaryl compounds as pikk inhibitors
11/18/2010CA2760741A1 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
11/18/2010CA2760340A1 Azacyclic spiroderivatives as hsl inhibitors
11/18/2010CA2760329A1 Uracyl spirooxetane nucleosides
11/18/2010CA2760259A1 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
11/18/2010CA2760219A1 Oligomer-containing substituted aromatic triazine compounds
11/18/2010CA2760205A1 Fused tricyclic aryl compounds useful for the treatment of viral diseases
11/18/2010CA2760179A1 Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
11/18/2010CA2760084A1 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
11/18/2010CA2759884A1 [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
11/18/2010CA2759838A1 Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
11/18/2010CA2759836A1 Humanized axl antibodies
11/18/2010CA2759546A1 A method and composition for the control of ectoparasites
11/18/2010CA2759500A1 Thieno [2,3-b]pyridine derivatives as viral replication inhibitors
11/18/2010CA2759196A1 Novel crystalline polymorph of sitagliptin dihydrogen phosphate
11/18/2010CA2759180A1 Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
11/18/2010CA2759077A1 Sitagliptin synthesis
11/18/2010CA2758675A1 Novel oxazolidinone derivatives
11/18/2010CA2758202A1 Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
11/17/2010EP2251359A1 Synthesis of Lipoamide-Grafted High Molecular Compound and Method Therefor
11/17/2010EP2251355A1 Treatment with anti-VEGF antibodies
11/17/2010EP2251350A2 RORalpha promoting the induction of Bmal1
11/17/2010EP2251344A1 Formulation of boronic acid compounds
11/17/2010EP2251343A1 Imidazothiazoles as p38-kinase-inhibitors
11/17/2010EP2251341A1 Heterocyclic Janus kinase 3 inhibitors
11/17/2010EP2251340A1 Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof
11/17/2010EP2251339A2 Compounds
11/17/2010EP2251338A2 Organic compounds
11/17/2010EP2251337A1 Dihydropyridine calcium antagonist compounds, preparation methods and medical uses thereof
11/17/2010EP2251333A1 Biphenyl derivatives as P-38 kinase inhibitors
11/17/2010EP2251332A1 The aromatic ring triazine derivatives and the uses thereof
11/17/2010EP2251330A1 4-Hydroxybenzomorphans
11/17/2010EP2251328A1 Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1h)pyridone, the preparation methods, compositions and applications thereof
11/17/2010EP2251327A2 Heterocyclic inhibitors of MEK and methods of use thereof
11/17/2010EP2251326A1 Heterocyclic compound
11/17/2010EP2251320A1 Crystalline form of tigecycline and processes for preparation thereof
11/17/2010EP2251042A2 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
11/17/2010EP2251040A1 Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
11/17/2010EP2251039A2 Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same
11/17/2010EP2251023A1 Anti-methicillin-resistant staphylococcus aureus agent and anti-vancomycin-resistant enterococcus agent
11/17/2010EP2251017A1 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
11/17/2010EP2251016A2 Topical use of hyaluronic acid with folmogenic action for the treatment and prophylaxys of pathologies of the respiratory tract.
11/17/2010EP2251015A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
11/17/2010EP2251014A1 Combined use of cholestanol derivative
11/17/2010EP2251013A2 Use of inositol-tripyrophosphate in treating Alzheimer's disease, stroke or osteoporosis
11/17/2010EP2251012A1 Tablet having improved elution properties
11/17/2010EP2251011A1 Solid preparation for oral administration
11/17/2010EP2251010A1 Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
11/17/2010EP2251009A1 Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
11/17/2010EP2251008A1 Methods for reducing the effects of stress on skin condition
11/17/2010EP2251007A2 Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
11/17/2010EP2251005A1 Orally disintegrating tablets
11/17/2010EP2251004A2 Pharmaceutical or cosmetic composition and a mixed solubilisation method for the production thereof
11/17/2010EP2251001A1 Skin whitening agent and external preparation for the skin
11/17/2010EP2251000A1 Skin whitening agent and external preparation for the skin
11/17/2010EP2250999A1 Skin whitening agent and external preparation for the skin
11/17/2010EP2250998A1 Skin whitening agent and external preparation for the skin
11/17/2010EP2250996A2 Method of enhancing hair growth
11/17/2010EP2250911A1 Weight-loss supplement
1 ... 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 ... 7860